Alnylam Pharma (ALNY) Tops Q4 EPS by 46c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $239.56 -2.42%
EPS Growth %: -39.0%
Financial Fact:
Total operating expenses: 101.16M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: -39.0%
Financial Fact:
Total operating expenses: 101.16M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of ($1.39), $0.46 better than the analyst estimate of ($1.85). Revenue for the quarter came in at $335.04 million versus the consensus estimate of $312.2 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Element Solutions (ESI) PT Lowered to $47 at UBS, Buy Rating Maintained
- DraftKings Inc. (DKNG) PT Lowered to $48 at UBS on Updated Estimates Post Q2
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
